In Vivo Anticoagulant Properties of a Novel Nucleotide-Based Thrombin Inhibitor and Demonstration of Regional Anticoagulation in Extracorporeal Circuits

By Linda C. Griffin, George F. Tidmarsh, Louis C. Bock, John J. Toole, and Lawrence L.K. Leung

Using a novel in vitro selection/amplification technique, we have recently identified a new class of thrombin inhibitors based on single-stranded DNA oligonucleotides. One oligonucleotide, GGTTGGGCTGTTGGG (thrombin aptamer), showed potent anticoagulant activity in vitro. We have initiated pharmacologic studies in cynomolgus monkeys to study the thrombin aptamer's in vivo anticoagulant properties. Upon infusion of the thrombin aptamer, anticoagulation was rapidly achieved, with a plateau reached within 10 minutes. There was a linear dose-response relationship between thrombin aptamer infusion rate and prolongation of plasma prothrombin time. Ten minutes after the infusion was stopped, no prolongation of prothrombin time was observed, indicating that the thrombin aptamer has an extremely short in vivo half-life, estimated to be 108 ± 14 seconds. In addition, inhibition of thrombin-induced platelet aggregation in platelet-rich plasma was observed ex vivo without an effect on collagen-induced aggregation, indicating that the inhibition was specific for thrombin and not due to a nonspecific inhibitory effect on platelets. To exploit the short in vivo half-life of the thrombin aptamer, its ability to achieve regional anticoagulation in an extracorporeal hemofiltration circuit in sheep was tested. Doubling of the prothrombin time in the circuit was observed, whereas the systemic prothrombin time was minimally prolonged. We conclude that the thrombin aptamer is a potent anticoagulant in vivo, and specifically inhibits thrombin-induced platelet aggregation ex vivo. The rapid onset of action and short half-life in vivo suggest that the thrombin aptamer may be useful in anticoagulation with extracorporeal circuits and may have distinct advantages in certain acute clinical settings.

© 1993 by The American Society of Hematology.
jugular venous catheters. An Amicon mini-flow hemofiltration catheter was inserted for blood sampling. Access for arterial-venous tions.

phenobarbital. Once the animal was adequately sedated, endotra-
tion of a peripheral intravenous (IV) catheter and administration of

each blood sample. The was used to withdraw the saline or heparin from the sampling cath-
diately assayed.

whole blood sample was immediately transferred to a sodium ci-
gation ex vivo, catheter patency was maintained by a continuous
hemofiltration was established by placement of carotid artery and
animal was lightly anesthesized with ketamine HCI before the inser-
tion. A new syringe was used to withdraw each blood sample. The

sizer (Millipore, Waters, MA) using standard methods as previously
described. The synthetic DNA was purified by polystyrene reverse-
phase high performance liquid chromatography (HPLC), de-trityl-
ated, and secondarily purified using C18 HPLC to greater than
97% homogeneity by ion exchange analysis. The purified thrombin ap-ter was desalted by C18 reverse-phase HPLC and then con-
verted to the Na+ form using BIORAD AG50W-X8 (BioRad, Rich-
mond, CA) for counterion exchange. A stock solution was prepared
dissolving the thrombin ap-ter at approximately 20 mg/mL in
20 mmol/L sodium phosphate buffer (pH 7.4) and sterile titering.

Cynomolgus monkeys. Normal adult male cynomolgus mon-
keys (Macaca fascicularis) were used in these studies. The animals
weighed 4.2 to 5.5 kg and had been observed to be disease free for at
least 10 days before study initiation. All procedures were approved
by the New Mexico Regional Primate Research Laboratory Animal
Care and Use Committee and performed in compliance with the
Animal Welfare Act and the Good Laboratory Practice Regula-
tions.

Thrombin ap-ter dosing procedure. The animals were lightly anesthetized (~10 mg/kg of ketamine HCI) on the day of the study,
weighed, and placed in primate restraint chairs. A short (1-inch)
catheter was placed into a cephalic vein for dose administration and
a long (12-inch) catheter was placed in the saphenous vein for blood
collection. Animals were allowed to recover from the anesthetic
and acclimate to the restraint system before initiation of the study.
The animals were divided into three groups. Four animals were
infused with thrombin ap-ter at a constant rate of 0.3 mg/kg/min
for 60 minutes (constant rate infusion group). Two animals were
infused with thrombin ap-ter at variable rates of 0.075 mg/kg/
min, 0.15 mg/kg/min, 0.3 mg/kg/min, and 0.6 mg/kg/min, each
for 15 minutes (variable rate infusion group). One animal was in-
fused with saline at a constant rate of 0.5 mL/min for 60 minutes
(saline control). In the constant rate infusion group, a 1 U/mL
sodium heparin flush was used to maintain catheter patency. In
the variable rate infusion group, because residual heparin in the blood
catheter interfered with thrombin-induced platelet aggre-
gation ex vivo, catheter patency was maintained by a continuous
infusion (5 mL/h) of sterile saline through the blood collection
catheter for the duration of the study.

Blood sampling procedure. Blood samples (1.8 or 2.7 mL) were
collected from each animal before infusion; 2, 10, 30, and 60 min-
dutes during the constant rate infusion; and 2, 5, 10, 15, 20, 30, and
45 minutes after the infusion. Blood samples were drawn during the
variable rate infusion before infusion: 5, 15, 20, 30, 35, 45, 50, and
60 minutes during infusion; and 10 and 30 minutes after the infu-
sion. Immediately before each blood sample was taken, a syringe
was used to withdraw the saline or heparin from the sampling cath-
eter. A new syringe was used to withdraw each blood sample. The
whole blood sample was immediately transferred to a sodium ci-
trate tube and centrifuged at 4°C. Plasma was separated and imme-
diately assayed.

Hemofiltration studies in the sheep. A 2-month-old, male sheep
weighing 22.7 kg was used for the hemofiltration experiment. The
animal was lightly anesthesized with ketamine HCI before the inser-
tion of a peripheral intravenous (IV) catheter and administration of
phenobarbital. Once the animal was adequately sedated, endotra-
cheal intubation was performed; the animal was maintained under
general anesthesia throughout the experiment. A femoral venous
catheter was inserted for blood sampling. Access for arterial-venous
hemofiltration was established by placement of carotid artery and
jugular venous catheters. An Amicon mini-flow hemofiltration
unit (Amicon, Danvers, MA) was flushed with normal saline and
connected to the carotid arterial and jugular venous catheters. Con-
stant blood flow was maintained at 50 mL/min by an in-line centrif-
ugal pump. The thrombin ap-ter was infused into the arterial
arm of the hemofiltration circuit at a constant rate calculated to
achieve 3 μmol/L final concentration in the circuit. Blood samples
for prothrombin time (PT) analysis were drawn from the circuit just
before the hemofilter. For comparison, timed samples were drawn
from the femoral venous catheter to measure the extent of systemic
anticoagulation. Hemofiltration under these conditions was per-
formed for 2 hours. Similarly, hemodialysis was performed at a
blood flow rate of 100 mL/min using a CA-90 hollow fiber hemodi-
alysis cartridge (Baxter, McGaw Park, IL).

PT assays. Blood samples were centrifuged (2,000g for 5 min-
utes) and the plasma separated for standard PT assays. PT times
were measured using an automated fibrometer (Becton Dickinson,
Mountain View, CA) using Sigma (St Louis, MO) reagents as per
the manufacturer’s specifications.

Platelet aggregometry. Platelet aggregation was performed with
platelet-rich plasma (PRP) (150g for 20 minutes) in the standard
manner (incubated at 37°C for 5 minutes before assay) using a
Chronolog dual-channel aggregometer (Chrono-Log Corp, Hav-
town, PA). Human thrombin (1 U/mL) (Haematologics, Essex Jet,
VT) and collagen (Chrono-Log) were used as platelet agonists.

RESULTS

In vitro dose response of thrombin ap-ter in plasma. The relationship between thrombin ap-ter concentration and prolongation of PT in cynomolgus monkey plasma was determined in vitro (Fig 1). The results show a linear dose response in the range studied with a doubling of the control PT at approximately 2 μmol/L thrombin ap-
ramer in plasma. This standard curve was used to determine the levels of thrombin ap-ter in plasma at time points
during and after IV infusion of thrombin ap-ter.

Constant rate infusion of thrombin ap-ter in vivo. The time course of thrombin ap-ter-mediated anticoagulation during a constant rate IV infusion was studied (Fig 2). Thrombin ap-ter was infused into four animals at a rate of
0.3 mg/kg/min over a period of 1 hour. Saline alone was
infused into one animal as a control. Anticoagulation was
rapidly achieved, with a plateau reached within 10 minutes
at 1.7 to 2.0 times control PT, corresponding to calculated
in vivo plasma concentrations of 1.5 to 2.1 μmol/L. When
the infusion was stopped, there was a rapid reversal of the
anticoagulant effect such that at 10 minutes after the infu-
sion, the PT had returned to baseline. The data indicated that
the in vivo half-life of the thrombin ap-ter is ex-
tremely short. Based on an exponential fit of the data, from
the termination of infusion to 300 seconds, the T1/2 was
determined to be 108 ± 14 seconds.

Variable rate infusion of thrombin ap-ter in vivo. To
determine if the anticoagulant effect was dose dependent,
an increasing, variable dose infusion was studied. Throm-
bin ap-ter was infused into two animals at an initial rate of
0.075 mg/kg/min. The infusion rate was doubled every
15 minutes over a period of 1 hour. There was a rapid re-
sponse in PT to the increasing dose in thrombin ap-ter (Fig 3A) and a linear dose-response relationship between
thrombin ap-ter infusion rate and prolongation in PT in plasma
was observed (1.2 to 2.2 times control PT) (Fig 3B).

Thrombin ap-ter inhibition of specific thrombin-in-
IN VIVO ANTICOAGULATION BY THROMBIN APTAMER

Fig 1. Relationship between thrombin aptamer concentrations and prolongation in plasma PT in vitro from two cynomolgus monkeys. Control PT was 12 to 13 seconds.

duced platelet aggregation ex vivo. The effect of thrombin aptamer on thrombin- or collagen-induced platelet aggregation in PRP was determined ex vivo in samples collected from the variable dose infusion study. Even at the lowest dose (0.075 mg/kg/min), thrombin aptamer effectively inhibited thrombin-induced platelet aggregation (Fig 4B). It should be noted that at this low dose of thrombin aptamer, platelet shape change was observed as evidenced by a decrease in light transmission after thrombin addition, indicating that there was sufficient thrombin to bind to the platelet thrombin receptor to cause partial platelet activation. This is consistent with the reduced amplitude in the aggregation tracing upon subsequent collagen stimulation, suggesting that platelets were partially activated after thrombin stimulation and thus became partially refractory to collagen (Fig 4B). At higher rates of thrombin aptamer infusion, shape change was completely abolished and the full platelet aggregation response to collagen was observed (Fig 4D and E). Even at the highest dose of thrombin aptamer, platelets responded normally to collagen, indicating that the thrombin aptamer inhibitory effect is specific for thrombin interaction with the platelet thrombin receptor, and not due to nonspecific inhibitory effects on platelets. Similar to the anticoagulant effect, platelets responded normally to throm-

Fig 2. Time course of thrombin aptamer-mediated anticoagulation (PT) during IV infusion. Thrombin aptamer was infused into four animals at a rate of 0.3 mg/kg/min over a period of 1 hour (●) (mean ± SD, n = 4). Saline alone was infused into one animal as a control (○). Blood samples were collected from each animal at different time points and assayed. Anticoagulation was rapidly achieved with a plateau reached within 10 minutes at 1.7 to 2.0 times control PT. Ten minutes after the infusion was stopped, no prolongation of PT was observed, indicating a very short in vivo half-life of the thrombin aptamer.

Fig 3. (A) Dose-response of increasing thrombin aptamer infusion and prolongation in plasma PT. Thrombin aptamer was infused into two animals at a rate of (A) 0.075 mg/kg/min, (B) 0.15 mg/kg/min, (C) 0.30 mg/kg/min, and (D) 0.60 mg/kg/min. Blood samples were collected at different time points from each animal (○) and assayed. Control PT was 12 to 13 seconds. (B) Relationship between thrombin aptamer infusion rate and PT in plasma from two cynomolgus monkeys. Control PT was 12 to 13 seconds. The PT responded linearly to increasing dose (1.2 to 2.2 times control PT).
Fig 4. (A through F) Platelet aggregation studies showing the effect of IV infusion of thrombin aptamer at different rates on thrombin-induced (T) or collagen-induced (C) platelet aggregation in PRP ex vivo.

Hematology and serum chemistry. A decrease in the hematocrit (15% to 17% decrease from 100% baseline) was observed in all three groups of animals (constant rate infusion, variable rate infusion, and saline control) that is most likely related to hemodilution and multiple blood drawing. A significant increase in the white blood cell (WBC) count was also seen in all three groups at 30 minutes postinfusion (mean WBC 23,820/µL for animals receiving thrombin aptamers vs 21,100/µL for the saline control animal), probably due to stress-related neutrophilia. Neutrophil and WBC counts returned to near normal levels 24 hours after infusion. There was a moderate increase (2 to 3 times baseline) in serum creatine phosphokinase (CPK) in all groups, including control, at 30 minutes and 24 hours postinfusion. One animal in the constant thrombin aptamer infusion group had a marked increase in CPK. Electrophoresis of the serum sample showed 99.6% CPK MM isotype, indicating that skeletal muscle was the primary source of this enzyme. Trauma associated with chair restraint and other study procedures could account for the increase in serum CPK. All other serum chemistry values, including electrolytes, liver enzymes, and kidney function tests, were normal after infusion of thrombin aptamer. All the animals tolerated the aptamer infusion without any problems and remained well after the experiments.

Demonstration of regional anticoagulation in sheep hemofiltration. To exploit the short in vivo half-life of the thrombin aptamer, its ability to achieve regional anticoagulation in an extracorporeal circuit was tested. Regional anticoagulation is defined as adequate prolongation of PT within the extracorporeal circuit while maintaining the PT in the systemic circulation at or near baseline. Hemofiltration was performed in the sheep, with the thrombin aptamer infused just proximal to the hemofiltration unit. Clotting times were determined from samples taken simulta-
The hemofiltration circuit (PT range, 40 to 45 seconds; PT baseline, 21.7 seconds), whereas the systemic PT remained essentially unchanged or only slightly prolonged (Fig 5), clearly showing regional anticoagulation in an extracorporeal circuit by the thrombin aptamer. Similar results were observed in hemodialysis performed on a separate sheep (data not shown).

**DISCUSSION**

Using a novel selection and amplification technique, we have recently identified new thrombin inhibitors based on ssDNA oligonucleotides. Because these specific ssDNA oligonucleotides represent a new class of thrombin inhibitor, it is critical to assess their in vivo anticoagulant efficacy and pharmacology. In this study, we have chosen a synthetic 15-mer oligonucleotide (thrombin aptamer), incorporating the active consensus sequence, and infused it intravenously into cynomolgus monkeys. The thrombin aptamer effectively prolonged the PT in a dose-dependent manner and specifically inhibited thrombin-induced platelet aggregation ex vivo (Figs 2 through 4). The animals tolerated the infusion of thrombin aptamer well without clinically evident side effects and the data indicate that it has potent anticoagulant efficacy in vivo.

The thrombin aptamer has a short half-life in vivo of approximately 108 seconds. Previous studies have shown that unmodified ssDNA oligonucleotides have a half-life of less than 1 minute after IV bolus injection in mice or rats. Our data are consistent with those observations. It is unlikely that this short half-life is due to rapid degradation of the ssDNA aptamer by plasma exonuclease activity. In contrast to RNA, ssDNA is much more resistant to exonuclease, and the in vitro half-life of the thrombin aptamer in human plasma has been estimated to be approximately 30 minutes (data not shown). The observation that the thrombin aptamer has a significantly longer plasma half-life in vitro also rules out the possibility that the thrombin aptamer is rapidly inactivated by nonspecific binding to plasma proteins. In addition, the in vivo half-life of the aptamer was not substantially prolonged after a 60-minute infusion as compared with an IV bolus injection (data not shown), suggesting that saturation of nonspecific binding sites in plasma or other compartments in vivo does not play a major role in determining the short half-life. More recently, we have developed an HPLC assay to directly measure the plasma concentration of the thrombin aptamer and have shown that the short half-life directly correlated with decreasing plasma concentration (W. Lee, J. Fishback, J. P. Shaw, personal communication, June 1992).

Previous studies suggest that cellular uptake of unmodified phosphodiester-linked oligonucleotides involves endocytosis, apparently mediated by specific saturable cell surface receptors. Rapid uptake of ssDNA by the liver has been observed after IV bolus injection in mice. Wide tissue distribution of modified oligonucleotides after IV injection has been reported. Whether the rapid clearance of the unmodified ssDNA thrombin aptamer is due to widespread cellular uptake and tissue distribution remains to be determined.

Hemodialysis in the presence of systemic anticoagulation with heparin carries a significant risk of clinically important hemorrhage, with a reported incidence of 10% to 19%. We have exploited the short in vivo half-life of the thrombin aptamer in achieving regional anticoagulation in an extracorporeal hemofiltration circuit, with the PT in the circuit maintained at 2× baseline whereas the systemic PT was minimally prolonged (Fig 5). Regional anticoagulation is desirable in clinical situations in which systemic anticoagulation poses a substantial risk for major hemorrhage, such as patients with uremic pericarditis, acute renal failure, active gastrointestinal bleeding, and recent cardiovascular surgery.

An additional advantage of a potent thrombin inhibitor with a short half-life is obviating the need for reversal of the anticoagulant effect. The anticoagulant effect of heparin is most commonly reversed with protamine sulfate, which is routinely performed after cardiopulmonary bypass surgery. However, protamine sulfate can cause hypotension by direct vasoconstriction. An anaphylactoid type reaction, associated with profound shock that is often fatal, has also been described. Presensitization of the susceptible patients to protamine by exposure to protamine in NPH or protamine-zinc insulin has been implicated. A potent direct thrombin inhibitor with a short half-life that can provide adequate anticoagulation during cardiopulmonary bypass surgery without the subsequent need for reversal will be of considerable clinical interest.

In addition to its potent anticoagulant property, we have recently shown that the synthetic thrombin aptamer inhibits clot-bound thrombin and reduces arterial thrombus formation in an ex vivo whole artery angioplasty model. In conclusion, rapid in vivo clearance of the thrombin aptamer provides an opportunity for drug development in certain clinical settings in which regional anticoagulation in
extracorporeal circuits is desirable (eg, hemodialysis and hemofiltration). This aptamer, composed of only natural nucleotides, is nontoxic even when administered at doses that achieve systemic anticoagulation. Finally, this aptamer provides a lead for further drug design by a variety of chemical modifications, including the phosphodiester backbone, the base, and the sugar moieties, to enhance its pharmacologic and therapeutic properties. These modifications are guided by a knowledge of the tertiary structure of the thrombin aptamer. Thus, aptamer technology represents a powerful new approach for rapid drug discovery and development.

ACKNOWLEDGMENT

We acknowledge Belinda Burnett and Dr Gene B. Fuller (New Mexico Regional Primate Research Laboratories) for their help in the primate studies and Drs William Rhine and Peter Yorgin (Stanford University Medical Center, Department of Pediatrics) for their help in the sheep studies. We also thank Regan Shea, Sarah McCurdy, Terry Terhorst, and Sonja Gerard for large-scale synthesis of thrombin aptamer.

REFERENCES

In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits

LC Griffin, GF Tidmarsh, LC Bock, JJ Toole and LL Leung